New drugs and their potential use against drug-resistant malaria.
D000634:Aminoquinolines / Q000627:therapeutic use; D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D037621:Artemisinins; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D015767:Mefloquine; D051379:Mice; D009285:Naphthoquinones / Q000627:therapeutic use; D010963:Plasmodium falciparum / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism; D011739:Pyrimethamine / Q000008:administration & dosage / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D012717:Sesquiterpenes / Q000627:therapeutic use; D013413:Sulfadoxine / Q000008:administration & dosage / Q000627:therapeutic use
D000634:Aminoquinolines; D000962:Antimalarials; D037621:Artemisinins; D009285:Naphthoquinones; D011804:Quinolines; D012717:Sesquiterpenes; C044408:WR 225448; D013413:Sulfadoxine; C045010:BW 58C; C031327:artemisinin; D015767:Mefloquine; D011739:Pyrimethamine